ArticleOncotarget2016

Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.

Ana Batlle-López et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.